A5038597185- Hemophilia Treatment and Research
- Platelet Disorders and Treatments
- Blood Coagulation and Thrombosis Mechanisms
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Chronic Myeloid Leukemia Treatments
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Cancer-related gene regulation
- Hemostasis and retained surgical items
- Blood groups and transfusion
- Protease and Inhibitor Mechanisms
- Blood properties and coagulation
- Iron Metabolism and Disorders
- Hemoglobinopathies and Related Disorders
- Heparin-Induced Thrombocytopenia and Thrombosis
- Antiplatelet Therapy and Cardiovascular Diseases
- Venous Thromboembolism Diagnosis and Management
- Diabetes Treatment and Management
- Chronic Lymphocytic Leukemia Research
- Blood disorders and treatments
- Cardiomyopathy and Myosin Studies
- HIV/AIDS Research and Interventions
- Blood donation and transfusion practices
- FinTech, Crowdfunding, Digital Finance
- Cardiac Fibrosis and Remodeling
- Musculoskeletal synovial abnormalities and treatments
Indiana Hemophilia and Thrombosis Center
2016-2025
Birmingham Community Healthcare NHS Trust
2025
University of Pennsylvania
2024
Ege University
2024
Pfizer (United States)
2024
University of Pittsburgh
2020
Northwestern University
2017
Michigan State University
2008-2015
Lutheran Hospital
2011
Children's Hospital of Michigan
2004
Effective ways to prevent arthropathy in severe hemophilia are unknown.We randomly assigned young boys with A regular infusions of recombinant factor VIII (prophylaxis) or an enhanced episodic infusion schedule at least three doses totaling a minimum 80 IU per kilogram body weight the time joint hemorrhage. The primary outcome was incidence bone cartilage damage as detected index joints (ankles, knees, and elbows) by radiography magnetic resonance imaging (MRI).Sixty-five younger than 30...
Concizumab is an anti-tissue factor pathway inhibitor monoclonal antibody designed to achieve hemostasis in all hemophilia types, with subcutaneous administration. A previous trial of concizumab (explorer4) established proof concept patients or B inhibitors.We conducted the explorer7 assess safety and efficacy inhibitors. Patients were randomly assigned a 1:2 ratio receive no prophylaxis for at least 24 weeks (group 1) 32 2) nonrandomly (groups 3 4). After treatment pause due nonfatal...
Recombinant factor VIIa (rFVIIa: NovoSeven; Novo Nordisk) has proven efficacy in the treatment of haemophilic patients with inhibitors. This prospective, double-blind study compared rFVIIa (35 vs. 90 microg/kg) initiation and maintenance haemostasis during after elective surgery. Patients inhibitors (FVIII, n = 26; FIX, 3) received immediately prior to incision; intraoperatively as needed; every 2 h for first 48 h; 2-6 following 3 days. Haemostasis was evaluated surgery, at 0, 8, 24 3, 4 5...
THE process of plasminogen activation is considered a critical component diverse biologic systems in humans. This reaction, which catalyzed vivo by tissue-type and urokinase-type activators, results the conversion to plasmin. Plasmin has an essential role maintaining vascular patency converting fibrin soluble fibrin-degradation products. In addition, activators have been implicated regulation embryogenesis, angiogenesis, ovulation, inflammation, tumor metastasis,1 suggesting that...
Summary. Recombinant activated factor VII (rFVIIa), licensed in 1999 for treatment of haemophilia patients with inhibitors (HI), represents an important advance the therapeutic armamentarium. Standard bolus dosing ranges from 90 to 120 mcg kg −1 every 2–3 h until arrest bleeding. As licensure, clinical use rFVIIa has increased and broadened. Clinicians now a wide dose range, 90–300 . High‐dose regimens may optimize thrombin generation or burst, allow prolonged interval. The Hemophilia...
Lack of detailed natural history and outcomes data for neonates toddlers with haemophilia hampers the provision optimal management disorder. We report an analysis prospective collected from 580 aged 0-2 years enrolled in Universal Data Collection (UDC) surveillance project Centers Disease Control Prevention (CDC). This study focuses on a cohort babies whose diagnosis was established before age two. The mode delivery, type severity haemophilia, onset timing haemorrhages, site(s) bleeding,...
Humans with a rare gene mutation in SERPINE1 live longer and show evidence of protection from aging-related morbidity.
Factor VIII replacement products have improved the care of patients with hemophilia A, but short half-life these affects patients' quality life. The recombinant factor ranges from 15 to 19 hours because von Willebrand chaperone effect. BIVV001 (rFVIIIFc-VWF-XTEN) is a novel fusion protein designed overcome this ceiling and maintain high sustained activity levels. Data are lacking on safety pharmacokinetics single-dose BIVV001.In phase 1-2a open-label trial, we consecutively assigned 16...
Abstract The Joint Outcome Study (JOS), a randomized controlled trial, demonstrated that children with severe hemophilia A (HA) initiating prophylactic factor VIII (FVIII) prior to age 2.5 years had reduced joint damage at 6 compared those treated episodic FVIII for bleeding. Continuation (JOS-C) evaluated early vs delayed prophylaxis effects on long-term health, following JOS participants 18 in an observational, partially retrospective study. Index magnetic resonance imaging (MRI) scores of...